Various flu shot benefit analyses are being presented during poster sessions in Boston, Massachusetts, this week. These data highlight the effectiveness and value of influenza vaccination across relevant age groups, risk profiles, and flu seasons with different levels of influenza burden.
An expansive analysis was announced today by CSL Seqirus, offering new data from three studies supporting the clinical, public health, and economic value of both cell-based and adjuvanted seasonal influenza vaccines.
Read More
